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ABSTRACT 
 
Evaluation of an Agar Dilution Method for Identification of Extended-Spectrum Beta-Lactamase 
(ESBL)-Producing Klebsiella pneumoniae in the Environment  
  
 
By 
 
Kimberly Okiemute Erukunuakpor 
April 2016 
 
 
 Antibiotic resistance is a serious global public health problem. ESBLs are enzymes that 
destroy expanded-spectrum beta-lactam antibiotics rendering these drugs ineffective. Infection 
with ESBL-producing K.pneumoniae are hard to treat and result in longer hospital stay and higher 
mortality rates. The Clinical Laboratory Standard Institute (CLSI) have standard methods for 
detection of ESBL producing strains of bacteria in infected patients to guide antibiotic therapy, 
reduce the risk of mortality and risk of transmission. The presence of K.pneumoniae and E.coli 
which produce ESBLs have been confirmed in natural environments such as soil and water but no 
standard methods exist to identify directly and quantify these bacteria to understand the risk of 
human exposure in these settings. The purpose of this research is to assess the ability of an agar 
dilution method, using a differential agar Bio-Rad Rapid E.coli 2 agar utilized in environmental 
water quality studies, to identify correctly ESBL-producing K.pneumoniae. The minimum 
inhibitory concentration (MIC) of ceftriaxone antibiotic for wild-type ESBL producing 
K.pneumoniae isolates were compared on Mueller-Hinton broth (MHB) and Bio-Rad Rapid E.coli 
2 agar. Using the MIC values, the isolates were classified as susceptible, intermediate or resistant. 
The MIC of wild-type strains of K.pneumoniae were above 4μg/mL for both methods on all 
susceptibility tests performed. The results of this research suggest that Bio-Rad Agar dilution 
method performed well, correctly identifying these strains as resistant to ceftriaxone, an indication 
of ESBL production. The Bio-Rad agar dilution method can be considered as a viable standard 
method for direct identification of ESBL-producing K.pneumoniae in natural environments. 
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Antibiotics once hailed as ‘miracle drugs’ are fast becoming ineffective due to resistance. 
Antibiotic resistance is the ability of an infectious bacterial species to evade the destructive effects 
of an antibiotic. Following the discovery of the first antibiotic -Penicillin- bacteria evolved to resist 
destruction (Casey, 2012). Bacteria resist the impact of antibiotics through three mechanisms: (i) 
destroying or altering the antibiotic structure, (ii) stopping the entry of the antibiotic to the target 
site, (iii) modifying the target site of the antibiotic (Neu, 1992).  
Antibiotic resistance is a serious global public health problem as it threatens the effective 
treatment of bacterial infections (WHO, 2014). The 2014 Antimicrobial Resistance Global 
Surveillance Report by the World Health Organization revealed a high prevalence of antibiotic-
resistant infections, with some WHO regions reporting up to 95% bacterial resistance to the most 
recently developed antibiotics (WHO, 2014). In the United States, data from the National Hospital 
Discharge Survey revealed a surge in hospitalizations for antibiotic-resistant infections, from 
37005 in 1997 to 169985 in 2006, an increase of 359% (Mainous, Diaz, Matheson, Gregorie, & 
Hueston, 2011). Furthermore, the Centers for Disease Control and Prevention estimates that over 
2million people are infected with resistant bacteria yearly in the US, 26,000 of which lead to death 
(CDC, 2013). Most of these infections are common health-care associated and community-
acquired infections (urinary tract infections, wound infections, bloodstream infections and 
pneumonia) caused by Staphylococcus aureus and species of the Enterobacteriaceae family which 
include Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) (Carey, 2012; CDC, 
2013).  
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Members of the Enterobacteriaceae family produce β-lactamases as resistance 
mechanisms. β-lactamases are bacterial enzymes that hydrolyze β-lactam antibiotics. β-lactam 
antibiotics are antibiotics that have a β-lactam ring in their structure such as penicillin derivatives, 
cephalosporins and related compounds. E. coli, K. pneumoniae and a few other members of the 
Enterobacteriaceae family have the ability to synthesize extended-spectrum β-lactamases 
(ESBLs). ESBLs are a group of β-lactamases that confer resistance to third-generation (extended-
spectrum) cephalosporins (e.g., cefotaxime, ceftriaxone, ceftazidime) and monobactams (e.g., 
aztreonam) which were developed to fight against β-lactamase-mediated bacterial resistance to 
antibiotics (Paterson & Bonomo, 2005; Pitout & Laupland, 2008). 
Epidemiologic studies in healthcare settings have revealed that ESBL-producing bacteria, 
particularly K. pneumoniae, constitute a grave threat. A study focused on patients with 
bloodstream infections found that after 72 hours of antibiotic therapy, patients infected with ESBL-
producing K. pneumoniae had a higher treatment failure rate than patients infected with non-ESBL 
K. pneumoniae. The study also reported significantly higher mortality rate among ESBL infected 
patients than non-ESBL infected patients, after 21 days of therapy (Tumbarello et al., 2006). A 
case-control study found that among patients -with urinary tract infections, respiratory tract 
infections, and bloodstream infections- cases infected with ESBL-producing K. pneumoniae had a 
longer mean hospital stay than controls infected with non-ESBL producing K. pneumoniae 
(Brooklyn Antibiotic Resistance Task Force, 2002). With the threat to infection control, clinical 
microbiology laboratories play a significant role in the appropriate management of patients to curb 
the spread of ESBL-producing K. pneumoniae through early detection. These laboratories 
primarily follow standard guidelines for antimicrobial susceptibility tests published by the US 
Clinical and Laboratory Standards Institute (CLSI) for detection of ESBL producing organisms 
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(CLSI, 2014). These methods assess the ability of the infecting organism to hydrolyze different 
cephalosporin antibiotics on microbiological media specifically structured for detecting ESBL 
production in clinical specimens (Pitout & Laupland, 2008).  
Numerous environmental studies, using varying methods, have explored the occurrence of 
ESBL-producing bacteria in places outside of healthcare settings. Several of these studies have 
confirmed the presence of ESBL-producing Enterobacteriaceae in environments where human-
pathogen interaction may occur. A study of food samples of animal origin found that 26% 
contained ESBL-producing E.coli (Jouini et al., 2007). Zurfluh et al. (2013) detected ESBL-
producing Enterobacteriaceae in up to 36% of 58 rivers and lakes sampled. ESBL-producing K. 
pneumoniae and E.coli have also been found in wastewater, soil and vegetables (Ben Said et al., 
2015; Prado et al., 2008). These studies emphasize the importance of understanding the 
dissemination of ESBL-producing bacteria in natural environments as they may serve as reservoirs 
for these bacteria.  
1.2 Purpose of study 
A guideline for methods using media designed for clinical specimens exists for 
determination of ESBL-production in infectious agents in healthcare settings (CLSI, 2014). ESBL 
detection aids in guiding patient therapy, active surveillance, and development of effective public 
health interventions to prevent the spread of health-care associated infections by ESBL-producing 
bacteria. These bacteria are also known to exist in environments outside of health-care settings and 
may contribute to the burden of infections with ESBL-producing bacteria. However, no standard 
methods are available for detecting and quantifying ESBL-producing bacteria in the environment. 
Most importantly, microbiological media for rapid identification of ESBL-producing bacteria in 
the environment are needed, because media used in clinical laboratories is often not selective 
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enough to use with environmental samples, which may contain many other competing organisms 
that interfere with detection of ESBL producing bacteria. Therefore, the objective of this research 
is to evaluate an agar dilution method for measuring the minimum inhibitory concentration of 
antibiotics against ESBL-producing K. pneumoniae using a microbiological culture media, Bio-
Rad Rapid E. coli 2 agar that is designed to isolate K. pneumoniae and E. coli from the 
environment.  
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CHAPTER II 
LITERATURE REVIEW 
2.1 Background 
Antibiotic resistant bacteria constitute a threat to infection treatment and control. Current 
research reveals that many pathogenic bacterial species —Klebsiella pneumoniae, Escherichia 
coli, Staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa, and species of 
Enterobacter, Salmonella, and Shigella — are now resistant to most antibiotics (WHO, 2014 
Livermore, 2003). The infections caused by these bacteria are common health-care associated and 
community-acquired infections such as urinary tract infections, wound infections, bloodstream 
infections and pneumonia. However, resistance leads to more severe outcomes from these 
infections (Carey 2012, CDC, 2013).  
Extended-spectrum β-lactamases (ESBLs) are enzymes produced by bacteria that confer 
resistance to expanded-spectrum antibiotics such as ceftriaxone, cefotaxime and aztreonam 
(Bradford, 2001). Most bacteria that produce ESBLs are members of the Enterobacteriaceae family 
which include Klebsiella pneumoniae and Escherichia coli (Thomson & Moland, 2000). Infection 
with ESBL-producing Klebsiella pneumoniae is associated with severe outcomes –higher risk of 
morbidity and mortality– compared to infection with non-ESBL producing K. pneumoniae, 
therefore, epidemiologic studies exploring the occurrence of infections with ESBL-producing 
bacteria have focused on this organism (Paterson & Bonomo, 2005).Furthermore, clinical 
microbiology laboratories play a significant role in patient management to curb the spread of this 
organism in clinical settings through early detection using standard guidelines published by the 
Clinical and Laboratory Standard Institute (CLSI, 2014). 
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ESBL-producing bacteria are known to exist in environments such as soil and water where 
human exposure may occur (D’Andrea, Arena, Pallecchi, & Rossolini, 2013). However, the 
contribution of these environments to the burden of infections with ESBL producing bacteria is 
unknown because no standard method exists to monitor and quantify these bacteria in areas outside 
of clinical settings. 
2.2 Extended-spectrum β-lactamases (ESBLs) 
Resistant bacteria synthesize β-lactamases enzymes which inactivate the effects of β-
lactam antibiotics.  β-lactam antibiotics are a class of antibiotics that have a β-lactam ring in their 
chemical structure; these include penicillin, cephalosporins and related compounds (Holten & 
Onusko, 2000).  New antibiotics, termed 'oxyimino-cephalosporins’ were developed, to address 
bacterial resistance to β-lactam antibiotics (Leggiadro, 1997). These new antibiotics were specially 
designed with a wider spectrum of activity to resist the effect of β-lactamases. However, the 
introduction of the new antibiotics in clinical practice saw the rapid emergence of strains of 
Klebsiella pneumoniae, Escherichia coli, and other gram-negative pathogens expressing new β-
lactamases, termed Extended-spectrum β-lactamases (ESBLs), that were able to degrade and 
confer resistance to these drugs (Bradford, 2001). 
“ESBLs are commonly defined as β-lactamases capable of conferring bacterial resistance 
to penicillins, first-, second-, and third-generation cephalosporins, and aztreonam by hydrolysis of 
these antibiotics, but are inhibited by β- lactamase inhibitors such as clavulanic acid” (Paterson & 
Bonomo, 2005). Most ESBLs are classified into three groups, TEM, SHV, and CTX-M, based on 
the β-lactamase enzyme they mutated from (Bush, Jacoby, & Medeiros, 1995). TEM-derived and 
SHV-derived ESBLs are found mainly in clinically isolated strains of Klebsiella pneumoniae and 
E.coli while the CTX-M-derived ESBLs are not limited to clinical isolates (Pitout, Nordmann, 
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Laupland, & Poirel, 2005). Epidemiologic surveillance suggests that the burden of community-
associated antibiotic-resistant infections caused by ESBL-producing E.coli can be attributed to the 
expression of CTX-M-derived ESBLs. A study by Pitout et al. (2004) that examined patients with 
community-onset infections caused by ESBL-producing E.coli found that 70% of the E.coli strains 
expressed CTX-M-derived ESBLs (Pitout et al., 2004). Another study that examined ESBL-
producing E.coli isolates from patients with community-acquired urinary tract infections revealed 
that 62% of the isolates were positive for were CTX-M derived ESBLs (Smet et al., 2010). 
Furthermore, a prospective observational study of five hospitals in the United States found that 
among patients with community-associated bacteremia, wound infections, and urinary tract 
infections caused by ESBL-producing E.coli, 91.3% of strains isolated were positive for CTX-M 
derived ESBLs (Doi et al., 2013). 
2.3 ESBL-Producing Klebsiella pneumoniae     
A review by Thomson & Moland (2000) found that members of the Enterobacteriaceae 
family most likely to produce ESBLs are K. pneumoniae, E. coli, Klebsiella oxytoca, and to a 
lesser extent Citrobacter, Enterobacter, Proteus, Salmonella and Serratia. Other non-enteric 
pathogens of public health importance also found to produce ESBLs are Acinetobacter baumannii 
and Pseudomonas aeruginosa (Thomson & Moland, 2000). Worldwide, K. pneumoniae and E.coli 
remain the primary ESBL-producing organisms of public health importance (Pitout & Laupland, 
2008). A report by the Infectious Disease Society of America revealed that ESBL-producing 
Klebsiella sp and E.coli were one of six major antibiotic-resistant pathogens to which new 
antibiotics are urgently needed (Talbot et al., 2006).  
Klebsiella pneumoniae, in particular, has been the focus of epidemiological investigations 
into the burden of infections caused by ESBL-producing organisms in healthcare settings. ESBL-
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producing K. pneumoniae is considered a grave threat in hospital settings because infection with 
this pathogen has been associated with more severe outcomes compared to non- ESBL producing 
K. pneumoniae. A case-control study by Lautenbach et al. (2001) found that median length of 
hospital stay was 1.76 times greater, and mortality was two times higher for patients infected with 
ESBL-producing K. pneumoniae compared to patients infected with non-ESBL producing K. 
pneumoniae (Lautenbach et al., 2001). A study focused on patients with bloodstream infections 
found that after 72 hours of antibiotic therapy, patients infected with ESBL-producing K. 
pneumoniae had a treatment failure rate that was two times higher than the failure rate for patients 
infected with non-ESBL K. pneumoniae. The study also reported significantly higher mortality 
rate among ESBL infected patients (52%) than non-ESBL infected patients (29%), after 21 days 
of therapy (Tumbarello et al. 2006). A case-control study found that among patients -with urinary 
tract infections, respiratory tract infections, and bloodstream infections- cases infected with ESBL-
producing K. pneumoniae had a longer mean hospital stay (29 days) than controls infected with 
non-ESBL producing K. pneumoniae (11days) (Brooklyn Antibiotic Resistance Task Force, 
2002). The adverse outcomes of infection with ESBL-producing K. pneumoniae establishes this 
pathogen as a serious public health threat. Therefore, it is important to detect the presence of this 
organism in clinical settings and areas where human-pathogen interaction may occur. 
2.4 Detection and Identification of ESBL-Producing Klebsiella pneumoniae 
Clinical microbiology laboratories play a significant role in the appropriate management 
of patients infected with ESBL-Producing K. pneumoniae through early detection and 
identification of this organism. The US Clinical and Laboratory Standards Institute (CLSI) have 
standard guidelines for detection of ESBL-production in members of the Enterobacteriaceae 
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family of bacteria specifically K. pneumoniae, K. oxytoca, E.coli, and Proteus mirabilis (CLSI, 
2014).   
The guideline outlines susceptibility testing methods – Broth dilution, Agar dilution and 
Disk diffusion methods – that assess the ability of these organisms to grow in the presence of 
different antibiotics. There are also methods outlined specifically for detecting ESBL production 
in clinical specimens. The standard microbiological media recommended for use on clinical 
specimens is the cation-adjusted Mueller-Hinton Broth (CAMHB) and the Mueller-Hinton Agar 
(MHA) (CLSI, 2014; Pitout & Laupland, 2008). The broth and agar dilution methods involve 
preparing a two-fold dilution of antibiotics in liquid (CAMHB for broth dilution) or solid (MHA 
for agar dilution) media, a standardized bacterial suspension of 1-5×105 colony forming units 
(CFU)/mL is inoculated into the liquid medium or spotted on the solid medium. Visible growth, 
evidenced by turbidity on the liquid medium and colony growth on the solid medium, is observed 
after a defined period (Jorgensen & Ferraro, 2009; Wiegand, Hilpert, & Hancock, 2008; CLSI, 
2014). The disk diffusion method involves the application of a paper antibiotic disk on solid media 
(MHA) inoculated with a standardized bacterial suspension of 1-2×108CFU/mL, after which zones 
of growth inhibition around the antibiotics are measured (Jorgensen & Ferraro, 2009; CLSI, 2014). 
The broth dilution and agar dilution methods provide quantitative results; that is the 
minimum inhibitory concentration (MIC). MIC is the lowest concentration of an antimicrobial 
agent that inhibits visible growth of a bacterium. The MIC is interpreted qualitatively using an 
MIC interpretive criteria/breakpoint that categorizes the infecting organism as susceptible, 
intermediate, or resistant (Jorgensen & Ferraro, 2009; Wiegand et al., 2008; CLSI, 2014). The disk 
diffusion method provides qualitative results based on a zone diameter interpretative criteria that 
categorize the infecting organism as susceptible, intermediate, or resistant (Jorgensen & Ferraro, 
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2009; CLSI, 2014). Results from these methods interpreted based on the MIC and zone diameter 
interpretative criteria or breakpoints determine antibiotic resistance. Using the CLSI guideline 
accurately, these methods have been shown to have a sensitivity and specificity of up to 94% and 
98%, respectively, in identifying ESBL-producing K. pneumoniae isolates (Wiegand, Geiss, 
Mack, Stürenburg, & Seifert, 2007).  
2.5 ESBL-producing Bacteria in the Environment 
Berkner, et al. (2014) stated that “since the beginning of the antibiotic era in the first half 
of the 20th century, antibiotics and antibiotic resistance genes have been introduced to or have 
spread to almost every ecosystem on earth.” The spread of antibiotic-resistant bacteria is evidenced 
by the detection and isolation of resistant bacteria from natural environments such as air, soil and 
naturally occurring water bodies and other nutrient-enriched environments such as wastewater, 
agricultural farms as well as agricultural products (Wellington et al., 2013).  
Environmental studies, exploring the occurrence of antibiotic resistant bacteria in various 
environments have confirmed the presence of ESBL-producing bacteria in these environments 
(D’Andrea et al., 2013; Zurfluh et al., 2013). A study looking at 58 naturally occurring rivers and 
lakes found that 36% of these waters contained ESBL-producing K. pneumoniae, E.coli and 
Enterobacter (Zurfluh et al. 2013). Another study found that 26% of food samples originating from 
farm animals contained ESBL-producing E.coli (Jouini et al. 2007). Another study looking at 
vegetables, soil and irrigation water samples collected from 18 different farm environments found 
that up to 30% of all samples contained ESBL-producing K. pneumoniae, E.coli, Enterobacter and 
Citrobacter (Ben Said et al. 2015). These studies confirm the colonization of nutrient-rich 
environments by ESBL-producing bacteria. These studies have utilized various susceptibility 
testing methods such as the CLSI broth dilution, agar dilution and disk diffusion tests. Other 
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susceptibility methods utilized include antimicrobial gradient methods such as the Etest and also 
automated instrument systems such as the Vitek 2 system.  
Wastewater, particularly hospital effluent, are described as “hotspots” for ESBL-producing 
bacteria (Hocquet, Muller, & Bertrand, 2016). Results from studies looking at levels of ESBL-
producing bacteria in wastewater from hospitals and communities show that concentrations of 
ESBL-producing E.coli can be as high as 6×1011cfu/mL (Bréchet et al., 2014; Kwak et al., 2015). 
Despite the knowledge of the severe outcomes of infection with ESBL-producing K. 
pneumoniae and evidence of the dissemination of this organism and other ESBL-producing 
bacteria in environments where human exposure may occur, no standard methods exist for 
monitoring these bacteria outside of clinical settings. Studies exploring the presence of ESBL 
producers in the environment have utilized various methodologies making it difficult to compare 
outcomes from these studies and to determine the relevance of the presence of these bacteria in 
these areas to human health. Therefore, it is important to research a reliable susceptibility testing 
method which may be utilized as a standard for detecting and quantifying ESBL-producing 
bacteria in the environment. 
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Chapter III 
METHODOLOGY 
3.1 Bacterial Isolates 
Wild-type (WT) Klebsiella pneumoniae were obtained from the clinical laboratory of the 
University of North Carolina Medical Center; these were isolated from three patients presenting 
at the medical center and identified as extended-spectrum ß-lactamase (ESBL) producing strains 
of K. pneumoniae that were resistant to the antibiotic ceftriaxone. These strains, labeled K. 
pneumoniae F9093593, K. pneumoniae G0165470 and K. pneumoniae G2082851, were streaked 
onto sheep’s blood agar plates and transported to the School of Public Health Laboratory, Georgia 
State University.  
Commercially available reference strains of bacteria, from the American Type Culture 
Collection (ATCC), were also obtained for use. The organisms used in this research were 
Escherichia coli ATCC 25922 (susceptible to ceftriaxone) and K. pneumoniae ATCC 700603 
(resistant to ceftriaxone) which are routinely utilized for quality control in antimicrobial 
susceptibility testing. 
3.1.1 Propagation of Bacterial Stocks 
Pure cultures of each isolate were prepared in quantity for use for the entire project. Briefly, 
an isolation streak plate of each original culture on sheep’s blood agar was made on Trypticase 
Soy Agar (TSA). One isolated colony was collected using a sterile wooden stick and inoculated 
into 100mL of Trypticase Soy Broth (TSB) then incubated with shaking at 37°C for 24 hours. 
After 24 hours, 20mL glycerol was added to the 100ml of inoculated TSB, then dispensed into 1ml 
tubes and stored in a refrigerator at -81°C. 
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3.2 Antimicrobial Agent 
Ceftriaxone antibiotic is the antimicrobial agent utilized for this research. Ceftriaxone is a 
third-generation ß-lactam antibiotic, and is one of the antibiotics that ESBL producing bacteria are 
resistant to. Stock solutions of ceftriaxone antibiotic used were prepared using the Clinical and 
Laboratory Standards Institute (CLSI) procedure for preparation of dilutions of antimicrobial 
agents for use in susceptibility tests (CLSI, 2014).  
3.3 Minimum Inhibitory Concentration (MIC) 
Minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial 
agent that inhibits visible growth of a bacterium. MICs for ceftriaxone obtained in this research 
are interpreted according to CLSI breakpoints for Enterobacteriaceae on ceftriaxone 
(≤1μg/mL=Susceptible; 2μg/mL=Intermediate; ≥4μg/mL =Resistant) (CLSI, 2014). 
3.3.1 Broth Macrodilution  
The CLSI Broth Macrodilution Method was used to determine the MIC of ceftriaxone 
antibiotic for each bacterial isolate. It uses cation-adjusted Mueller-Hinton Broth (CAMHB), the 
standard medium for antimicrobial susceptibility testing. Serial two-fold dilutions of ceftriaxone, 
starting at 0.125μg/mL up to 256μg/ml, were tested. These dilutions are the standard used in 
clinical laboratories to determine MIC of an antibiotic.  
For this procedure, TSA streak plates of bacterial strains were prepared and incubated at 
35°C for 24 hours. After incubation, isolated colonies were inoculated into a 10ml tube of 0.9% 
Sodium Chloride (NaCl) till the turbidity matched a 0.5% McFarland standard, to get a cell density 
of approximately 1-2×108 CFU/mL in the NaCl suspension. 150µL of the bacterial suspension was 
then diluted in 15ml CAMHB, to get an approximate bacterial concentration of 5×105 CFU/mL. 
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The CAMHB suspension was vortexed to get a homogeneous suspension of cells, and 1ml aliquots 
were then inoculated into CAMHB tubes with ceftriaxone antibiotic, at each two-fold dilution. 
These tubes were incubated at 35°C for 20 hours after which they were checked for visible growth. 
Each tube was marked growth or no growth, and the MIC recorded. 
3.3.2 Bio-Rad Agar Dilution  
The agar dilution method is an antibiotic susceptibility testing method that involves 
preparing two-fold dilutions of antibiotics in a growth medium, after which a standardized 
bacterial suspension is spotted on the medium. MIC of the antibiotic is determined by observation 
of visible growth, evidenced by colony appearance on the medium, after a defined period. The 
CLSI Agar Dilution method for MIC determination uses Mueller-Hinton Agar as the growth 
medium. For this research, Bio-Rad Rapid E. coli 2 agar was substituted for Mueller-Hinton Agar. 
The Bio-Rad Rapid E. coli 2 agar is a differential agar medium used for the direct identification 
and enumeration of E.coli and coliform bacteria, such as K. pneumoniae, in environmental water 
quality testing. The dilutions of ceftriaxone tested were two-fold serial dilutions starting at 
0.125μg/ml up to 512μg/ml. 
Briefly, TSA streak plates of bacterial strains were prepared and incubated at 35°C for 24 
hours. After incubation, isolated colonies were inoculated into a 10mL tube of 0.9% Sodium 
Chloride (NaCl) till the turbidity matched a 0.5% McFarland standard. Five spots of 1µL of the 
bacterial suspension were pipetted onto Bio-Rad Rapid E. coli 2 agar plates prepared with 
ceftriaxone antibiotic at each dilution. Plates were incubated at 35°C for 20 hours after which they 
were checked for visible growth. Each plate was marked growth or no growth, and the MIC 
recorded. 
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3.4 Spread Plate for Cell Count 
The spread plate procedure was used to determine further that the correct approximate 
bacterial cell density per inoculum had been utilized for each experiment. Five dilutions of 100µL 
of the NaCl suspension was prepared in tubes containing 900µL of TSB and spread plated on TSA. 
TSA plates were incubated at 35°C and colonies formed on plates were counted after 24hours. 
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Chapter IV 
RESULTS 
Duplicate susceptibility tests -using the CLSI cation-adjusted Muller-Hinton Broth 
Macrodilution method- for ceftriaxone antibiotic was determined for the quality control strains 
utilized in this experiment. The test results are interpreted according to the CLSI breakpoints for 
Enterobacteriaceae (≤1μg/mL=Susceptible; 2μg/mL=Intermediate; ≥4μg/mL =Resistant). If the 
broth macrodilution test is working properly E. coli ATCC 25922 should be susceptible to 
ceftriaxone and K. pneumoniae ATCC 700603 should be resistant.  
Table 4.1: Ceftriaxone MIC for Negative control (E. coli ATCC 25922) and Positive control 
(K. pneumoniae ATCC 700603) bacterial isolates using CLSI CAMHB macrodilution. 
Bacterial Isolate  
MIC (μg/mL) 
Test 1 Test 2 
E.coli ATCC 25922 0.125 (S) 0.125 (S) 
K. pneumoniae  ATCC 700603 8 (R) 4 (R) 
*S=Susceptible; R=Resistant 
Table 4.1 shows the MIC determined for these two isolates E. coli ATCC 25922 and K. 
pneumoniae ATCC 700603. The MIC of ceftriaxone for E. coli ATCC 25922 was at the lowest 
concentration tested (0.125μg/mL), showing susceptibility to ceftriaxone and for K. pneumoniae 
ATCC 700603 was at approximately 8μg/mL, showing resistance to ceftriaxone. 
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Table 4.2: Ceftriaxone MIC for Wild-Type and Control isolates 
 
TEST 1 
Bacterial Isolate  
MIC (μg/mL) 
CLSI Broth 
Macrodilution 
Bio-Rad Agar  
Dilution 
E.coli ATCC 25922 0.125 (S) 0.125 (S) 
K. pneumoniae ATCC 700603 ND 8 (R) 
K. pneumoniae F9092593 64 (R) 32(R) 
K. pneumoniae G0165470 >256 (R) >512 (R) 
K. pneumoniae G2082851 256 (R) 16 (R) 
 
TEST 2 
Bacterial Isolate  
MIC (μg/mL) 
CLSI Broth 
Macrodilution 
Bio-Rad Agar  
Dilution 
E.coli ATCC 25922 0.125 (S) 0.125 (S) 
K. pneumoniae ATCC 700603 8 (R) 4 (R) 
K. pneumoniae F9092593 16 (R) 16 (R) 
K. pneumoniae G0165470 >256 (R) >512 (R) 
K. pneumoniae G2082851 256 (R) 32 (R) 
 
TEST 3 
Bacterial Isolate  
MIC (μg/mL) 
CLSI Broth 
Macrodilution 
Bio-Rad Agar  
Dilution 
E.coli ATCC 25922  0.125 (S) 0.125 (S) 
K. pneumoniae ATCC 700603 4 (R) 4 (R) 
K. pneumoniae F9092593 256 (R) 64 (R) 
K. pneumoniae G0165470 >256 (R) >512 (R) 
K. pneumoniae G2082851 256 (R) 64 (R) 
*ND=Not determined 
 
Table 4.2 presents results from triplicate tests performed to determine MIC of ceftriaxone 
for all bacterial isolates using the CAMHB macrodilution and Bio-Rad Agar dilution methods. For 
both methods, on all three tests, the MIC of ceftriaxone for the non-ESBL producing control 
organism (E. coli ATCC 25922) was below 1μg/mL. Based on the CLSI breakpoint for 
Enterobacteriaceae, the Bio-Rad Agar with ceftriaxone added detected the susceptibility of E. coli 
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ATCC 25922. Almost identical results are observed for the ESBL-producing control organism (K. 
pneumoniae ATCC 700603), for both methods. MIC for ceftriaxone for this organism was 
≥4μg/mL on the Bio-Rad Agar with ceftriaxone added. Based on the CLSI breakpoint for 
Enterobacteriaceae, the Bio-Rad Agar with ceftriaxone added detected the resistance of K. 
pneumoniae ATCC 700603. The MIC results observed for the three Wild-Type Strains -K. 
pneumoniae F9092593, K. pneumoniae G0165470, and K. pneumoniae G2082851- confirmed 
their resistance to ceftriaxone. The MIC for ceftriaxone was above 4μg/mL for the three Wild-
Type Strains on all three susceptibility tests, for both methods. The Bio-Rad Agar with ceftriaxone 
added performed well in identifying these strains as ESBL producers. 
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Chapter V 
DISCUSSION 
5.1 Discussion 
Antibiotic resistance is a major public health issue (WHO, 2014). Resistance to antibiotics 
leads to therapy failure which results in severe outcomes from common treatable infections. 
Extended-spectrum β-lactamase (ESBL) enzymes, produced majorly by K. pneumoniae and E.coli, 
facilitate resistance to ceftriaxone, cefotaxime, and aztreonam considered to be among the most 
advanced antibiotics (Pitout & Laupland, 2008). Infection with K. pneumoniae strains and other 
bacteria synthesizing ESBLs lead to higher mortality (Lautenbach et al., 2001; Tumbarello et al., 
2006). The presence of ESBL producing bacteria in natural environments, such as soil and water, 
have been confirmed (Ben Said et al., 2015; Jouini et al., 2007; Zurfluh et al., 2013). Currently, no 
standard methods exist to monitor these bacteria in natural environments. This research was 
undertaken to evaluate an agar dilution method, using a growth medium –Bio-Rad Rapid E. coli 2 
agar– that is designed to isolate K. pneumoniae and E. coli from the environment. 
The results of this research revealed that compared to the CLSI broth macrodilution 
method, the Bio-Rad agar dilution method performed well in identifying the non-ESBL producing 
strain of E.coli (susceptible to ceftriaxone) and the ESBL producing strains of K. pneumoniae 
(resistant to ceftriaxone). Based on the CLSI interpretative criteria, E.coli ATCC 25922 is 
identified on the Bio-Rad agar with ceftriaxone added as susceptible to ceftriaxone because growth 
inhibition was observed at concentrations below 1μg/mL. Growth inhibition for K. pneumoniae 
ATCC 700603, K. pneumoniae F9092593, K. pneumoniae G0165470, and K. pneumoniae 
G2022851 were observed at concentrations at or above 4μg/mL identifying these strains as 
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resistant to ceftriaxone.  The minimum inhibitory concentration (MIC) of two isolates K. 
pneumoniae F9092593 and K. pneumoniae G2022851 did differ between repeat tests, with the 
MIC of K. pneumoniae G2022851 being up to 3 dilutions higher ( 256 on Broth macrodilution; 16 
on Bio-Rad agar dilution) on test one (Table 4.2). However, the variations in MIC is typical when 
multiple susceptibility tests are performed. 
The Bio-Rad Rapid E. coli 2 agar is a useful tool in environmental water quality studies 
for direct enumeration and identification of E.coli and coliforms, which includes K. pneumoniae, 
in environmental samples. The substitution of the standard Mueller-Hinton media with Bio-Rad 
Rapid E. coli 2 agar media on the agar dilution susceptibility test demonstrated a high precision 
level, identifying the ESBL producing and non-ESBL producing bacteria on all susceptibility tests 
performed. The results of this research also showed that the Bio-Rad agar had a high accuracy in 
identifying the three ESBL producing K. pneumoniae strains when compared to the Broth 
macrodilution results.  
The use of a standard method is critical to monitor and compare outcomes from 
environmental studies demonstrating the dissemination of ESBL producing bacteria in the 
environment. Monitoring these bacteria is important to determine the relevance of their presence 
in natural environments where human exposure may occur. This research demonstrates the 
accuracy of an agar dilution method using a differential media designed for use on environmental 
samples. This method, similar to the CLSI standard susceptibility method for clinical samples, 
may be utilized as a standard for monitoring ESBL producers in the environment.  
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5.2 Limitations 
For this research, Bio-Rad Rapid E. coli 2 agar was substituted for the standard Muller 
Hinton agar. MHA is recommended as the standard growth medium because it presents little or no 
interference to the activity of antibiotics being tested. From the results of this research, Bio-Rad 
Rapid E. coli 2 agar exhibited no interference to ceftriaxone antibiotic; this suggests that it may 
work well with other β-lactam antibiotics. However, further research is necessary to confirm that 
the Bio-Rad Rapid E. coli 2 agar indeed presents no interference to the activity of other antibiotics 
and is suitable as an antibiotic susceptibility testing growth medium. Additionally, the sample size 
for this research was restricted to three K. pneumoniae strains. Further research using a larger 
sample size as well as other strains of ESBL producing bacteria such as E.coli, Enterobacter, 
Pseudomonas aeruginosa, Acinetobacter baumannii is critical to validate the results from this 
research. Furthermore, due to the small sample size this research was unable to determine the 
sensitivity and specificity of the Bio-Rad agar dilution method. 
5.3 Future Research 
 The results from this research are promising. However, further evaluation of the Bio-Rad 
agar dilution method is necessary. Further research using β-lactam antibiotics, other than 
ceftriaxone, is necessary to confirm that the Bio-Rad Rapid E. coli 2 agar presents no interference 
to the activity of antibiotics and is suitable as an antibiotic susceptibility testing growth medium. 
Also, a larger sample size using various strains of ESBL producing bacteria such as E.coli, 
Enterobacter, Pseudomonas aeruginosa, Acinetobacter baumannii is critical to validate the results 
from this research and to determine the sensitivity and specificity of the method. 
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